belantamab mafodotin,pomalidomide,dexamethasone
gsk
['belantamab', 'dreamm-3', 'dreamm', 'mmsm']
aa6/ dreamm-3: belantamab vs pom/dex in rrmm (single vs doublet)
- rct, phase iii 2:1
- rrmm: lot 4
- triple rrmm:21%
- high risk cyto: 30% (excludes 1q)
- emd:18% #mmsm #myeloma #medtwitter #usmirc #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter